关注
Sara Tolaney
Sara Tolaney
Dana-Farber Cancer Institute
在 dfci.harvard.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
M Xing, WH Westra, RP Tufano, Y Cohen, E Rosenbaum, KJ Rhoden, ...
The Journal of Clinical Endocrinology & Metabolism 90 (12), 6373-6379, 2005
12272005
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete …
WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, ...
Journal of clinical oncology 33 (1), 13-21, 2015
11332015
Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis
R Barroso-Sousa, WT Barry, AC Garrido-Castro, FS Hodi, L Min, IE Krop, ...
JAMA oncology 4 (2), 173-182, 2018
9902018
Sacituzumab govitecan in metastatic triple-negative breast cancer
A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ...
New England journal of medicine 384 (16), 1529-1541, 2021
9152021
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ...
New England Journal of Medicine 372 (2), 134-141, 2015
8212015
Phase II trial of bicalutamide in patients with androgen receptor–positive, estrogen receptor–negative metastatic breast cancer
A Gucalp, S Tolaney, SJ Isakoff, JN Ingle, MC Liu, LA Carey, K Blackwell, ...
Clinical cancer research 19 (19), 5505-5512, 2013
8102013
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
VA Adalsteinsson, G Ha, SS Freeman, AD Choudhury, DG Stover, ...
Nature communications 8 (1), 1324, 2017
7932017
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
A Bardia, IA Mayer, LT Vahdat, SM Tolaney, SJ Isakoff, JR Diamond, ...
New England Journal of Medicine 380 (8), 741-751, 2019
7542019
Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study
LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ...
JAMA oncology 5 (1), 74-82, 2019
7052019
Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors
A Patnaik, LS Rosen, SM Tolaney, AW Tolcher, JW Goldman, L Gandhi, ...
Cancer discovery 6 (7), 740-753, 2016
6792016
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆
A Gennari, F André, CH Barrios, J Cortes, E de Azambuja, A DeMichele, ...
Annals of oncology 32 (12), 1475-1495, 2021
6722021
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2 Metastatic Breast Cancer
MN Dickler, SM Tolaney, HS Rugo, J Cortés, V Diéras, D Patt, H Wildiers, ...
Clinical Cancer Research 23 (17), 5218-5224, 2017
6552017
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE)
SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, ...
Journal of Clinical Oncology 38 (34), 3987-3998, 2020
6342020
HER2-low breast cancer: pathological and clinical landscape
P Tarantino, E Hamilton, SM Tolaney, J Cortes, S Morganti, E Ferraro, ...
Journal of Clinical Oncology 38 (17), 1951-1962, 2020
5042020
Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
LS Chang, R Barroso-Sousa, SM Tolaney, FS Hodi, UB Kaiser, L Min
Endocrine reviews 40 (1), 17-65, 2019
4652019
Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors
S Goel, Q Wang, AC Watt, SM Tolaney, DA Dillon, W Li, S Ramm, ...
Cancer cell 29 (3), 255-269, 2016
4352016
Role of immunotherapy in triple-negative breast cancer
TE Keenan, SM Tolaney
Journal of the National Comprehensive Cancer Network 18 (4), 479-489, 2020
4102020
Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer
A Bardia, IA Mayer, JR Diamond, RL Moroose, SJ Isakoff, AN Starodub, ...
Journal of Clinical Oncology 35 (19), 2141-2148, 2017
3802017
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
S Pernas, SM Tolaney
Therapeutic advances in medical oncology 11, 1758835919833519, 2019
3442019
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ...
JAMA oncology 5 (8), 1132-1140, 2019
3352019
系统目前无法执行此操作,请稍后再试。
文章 1–20